06 May 2024
18:00 CEST |
IPSEN |
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
|
20103015 Pharmaceuticals |
Share history |
06 May 2024
18:00 CEST |
IPSEN |
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
|
20103015 Pharmaceuticals |
Share history |
02 May 2024
07:30 CEST |
IPSEN |
Ipsen appoints Keira Driansky as EVP, President of North America
|
20103015 Pharmaceuticals |
Other subject |
02 May 2024
07:30 CEST |
IPSEN |
Ipsen nomme Keira Driansky, en qualité de Vice-Présidente Exécutive, et Présidente Amérique du Nord
|
20103015 Pharmaceuticals |
Other subject |
24 Apr 2024
07:00 CEST |
IPSEN |
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
|
20103015 Pharmaceuticals |
Commercial results |
24 Apr 2024
07:00 CEST |
IPSEN |
Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l'exercice 2024
|
20103015 Pharmaceuticals |
Commercial results |
22 Apr 2024
07:00 CEST |
IPSEN |
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
|
20103015 Pharmaceuticals |
Alliances and agreements |
22 Apr 2024
07:00 CEST |
IPSEN |
Ipsen et Skyhawk Therapeutics annoncent la signature d'un accord de collaboration de recherche visant le ciblage d’ARN dans les maladies neurologiques rares
|
20103015 Pharmaceuticals |
Alliances and agreements |
17 Apr 2024
18:00 CEST |
IPSEN |
Ipsen publishes its 2023 Universal Registration Document
|
20103015 Pharmaceuticals |
Corporate life |
17 Apr 2024
18:00 CEST |
IPSEN |
Ipsen publie son Document d’enregistrement universel 2023
|
20103015 Pharmaceuticals |
Corporate life |
08 Apr 2024
18:00 CEST |
IPSEN |
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
|
20103015 Pharmaceuticals |
Share history |
08 Apr 2024
18:00 CEST |
IPSEN |
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
|
20103015 Pharmaceuticals |
Share history |
02 Apr 2024
07:00 CEST |
IPSEN |
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
|
20103015 Pharmaceuticals |
Alliances and agreements |
02 Apr 2024
07:00 CEST |
IPSEN |
Ipsen et Sutro Biopharma annoncent la signature d'un accord exclusif de licence mondiale pour un conjugué anticorps-petite molecule ciblant les tumeurs solides
|
20103015 Pharmaceuticals |
Alliances and agreements |
07 Mar 2024
18:00 CET |
IPSEN |
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
|
20103015 Pharmaceuticals |
Share history |
07 Mar 2024
18:00 CET |
IPSEN |
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
|
20103015 Pharmaceuticals |
Share history |
15 Feb 2024
10:00 CET |
IPSEN |
Ipsen S.A. publishes its 2023 Consolidated Financial Statements
|
20103015 Pharmaceuticals |
Sales |
15 Feb 2024
10:00 CET |
IPSEN |
Ipsen S.A. publie ses comptes consolidés 2023
|
20103015 Pharmaceuticals |
Sales |
13 Feb 2024
22:08 CET |
IPSEN |
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA
|
20103015 Pharmaceuticals |
Products and services |
13 Feb 2024
22:08 CET |
IPSEN |
Ipsen reçoit l’approbation de la FDA pour le schéma thérapeutique incluant Onivyde®, un potentiel nouveau traitement de référence en première ligne dans l'adénocarcinome du pancréas métastatique
|
20103015 Pharmaceuticals |
Products and services |
08 Feb 2024
06:58 CET |
IPSEN |
Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
|
20103015 Pharmaceuticals |
Commercial results |
08 Feb 2024
06:58 CET |
IPSEN |
Après de solides résultats pour l’année 2023, Ipsen anticipe quatre lancements commerciaux en 2024.
|
20103015 Pharmaceuticals |
Commercial results |
06 Feb 2024
18:00 CET |
IPSEN |
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
|
20103015 Pharmaceuticals |
Share history |
06 Feb 2024
18:00 CET |
IPSEN |
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
|
20103015 Pharmaceuticals |
Share history |
22 Jan 2024
23:00 CET |
IPSEN |
Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024
|
20103015 Pharmaceuticals |
Products and services |
22 Jan 2024
23:00 CET |
IPSEN |
Ipsen présente les dernières données d'un essai de Phase III évaluant Cabometyx® en association avec une immunothérapie à l'occasion de l'édition 2024 de l'ASCO sur les cancers génito-urinaires
|
20103015 Pharmaceuticals |
Products and services |
08 Jan 2024
18:00 CET |
IPSEN |
Ipsen – Half year statement – 2023 12 31
|
20103015 Pharmaceuticals |
Other subject |
08 Jan 2024
18:00 CET |
IPSEN |
Ipsen – Bilan semestriel – 2023 12 31
|
20103015 Pharmaceuticals |
Other subject |
05 Jan 2024
18:00 CET |
IPSEN |
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
|
20103015 Pharmaceuticals |
Share history |
05 Jan 2024
18:00 CET |
IPSEN |
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
|
20103015 Pharmaceuticals |
Share history |
07 Dec 2023
18:49 CET |
IPSEN |
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
|
20103015 Pharmaceuticals |
Share history |
07 Dec 2023
18:49 CET |
IPSEN |
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
|
20103015 Pharmaceuticals |
Share history |
07 Dec 2023
07:00 CET |
IPSEN |
Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook
|
20103015 Pharmaceuticals |
Other subject |
07 Dec 2023
07:00 CET |
IPSEN |
Journée Investisseurs 2023 - Ipsen présente sa prochaine phase de croissance et de transformation et ses nouvelles perspectives à moyen terme
|
20103015 Pharmaceuticals |
Other subject |
07 Dec 2023
07:00 CET |
IPSEN |
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC
|
20103015 Pharmaceuticals |
Products and services |
07 Dec 2023
07:00 CET |
IPSEN |
Ipsen confirme la décision de la FDA d'accorder un examen prioritaire pour le dépôt du dossier de demande d'autorisation d'elafibranor dans le traitement de la cholangite biliaire primitive, une maladie cholestatique rare du foie
|
20103015 Pharmaceuticals |
Products and services |
14 Nov 2023
18:00 CET |
IPSEN |
IPSEN - Buy-back programme - Art 5 of MAR - Week 45 - 2023
|
20103015 Pharmaceuticals |
Share history |
14 Nov 2023
18:00 CET |
IPSEN |
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 45 - 2023
|
20103015 Pharmaceuticals |
Share history |
13 Nov 2023
22:30 CET |
IPSEN |
Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine
|
20103015 Pharmaceuticals |
Products and services |
13 Nov 2023
22:30 CET |
IPSEN |
Les résultats de l’essai pivot de Phase III ELATIVE® d’Ipsen avec élafibranor dans la PBC présentés comme données de dernière minute au congrès de l’AASLD et publiés dans le New England Journal of Medicine
|
20103015 Pharmaceuticals |
Products and services |
07 Nov 2023
18:00 CET |
IPSEN |
IPSEN - Buy-back programme - Art 5 of MAR - Week 44 - 2023
|
20103015 Pharmaceuticals |
Share history |
07 Nov 2023
18:00 CET |
IPSEN |
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 44 - 2023
|
20103015 Pharmaceuticals |
Share history |
06 Nov 2023
18:00 CET |
IPSEN |
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
|
20103015 Pharmaceuticals |
Share history |
06 Nov 2023
18:00 CET |
IPSEN |
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
|
20103015 Pharmaceuticals |
Share history |
31 Oct 2023
18:00 CET |
IPSEN |
IPSEN - Buy-back programme - Art 5 of MAR - Week 43 - 2023
|
20103015 Pharmaceuticals |
Share history |
31 Oct 2023
18:00 CET |
IPSEN |
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 43 - 2023
|
20103015 Pharmaceuticals |
Share history |
26 Oct 2023
07:00 CEST |
IPSEN |
Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance
|
20103015 Pharmaceuticals |
Commercial results |
26 Oct 2023
07:00 CEST |
IPSEN |
Ipsen enregistre une solide croissance de ses ventes au cours des neuf premiers mois de 2023 et confirme ses objectifs pour l’exercice en cours
|
20103015 Pharmaceuticals |
Commercial results |
24 Oct 2023
18:00 CEST |
IPSEN |
IPSEN - Buy-back program - Art 5 of MAR - Week 42 - 2023
|
20103015 Pharmaceuticals |
Share history |
24 Oct 2023
18:00 CEST |
IPSEN |
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 42 - 2023
|
20103015 Pharmaceuticals |
Share history |